COMP <GO>
CLLS vs TLSA // EV/EBITDA & P/E VALUATION
Cellectis S.A. (NASDAQ) VS. Tiziana Life Sciences Ltd. (NASDAQ) • 15-METRIC TALLY: CLLS 2
— TLSA 0
■ METRIC PARITY
LAST: $1.08 (-7.69%) • MKT CAP: $117.6M
valuation
—
LAST: $0.80 (-11.57%) • MKT CAP: $115.1M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLLS VS. TLSA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLLS | TLSA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.6 | 35.8 | +1.87 | CLLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $117.6M | $115.1M | $2.5M | CLLS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLLS REV | TLSA REV | CLLS GROSS % | TLSA GROSS % | CLLS FCF | TLSA FCF |
|---|---|---|---|---|---|---|
| INSPECT INDIVIDUAL XBRL MODELS AT CLLS FA <GO> AND TLSA FA <GO>. | ||||||
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLLS // BETA —
TLSA // BETA —